Immunodiagnostics Market Size to grow by USD 29545.4 million between 2024-2028
According to a research report “ Immunodiagnostics Market” by Product (Reagents and consumables, Immunodiagnostic systems) Application (Oncology and endocrinology, Hepatitis and retrovirus, Infectious disease, GI stool, Other applications) Geography (North America, Europe, Asia, Rest of World (ROW))- Global Forecast to 2028 published by Technavio, the market size is estimated to grow by USD 29545.4 million, at a CAGR of almost 13.64% during the forecast period. In the immunodiagnostics market, advanced research and development in nucleic acid expression, proteomics, and sequencing have led to the identification of molecular biomarkers, which are proteins, genes, hormones, and other molecular entities that aid in detecting the presence or absence of diseases. The technological advancements have compelled manufacturers to focus on high-growth clinical areas such as oncology, cardiac diseases, and women's health, leading to the development of assays for these conditions. This shift towards personalized medicine is anticipated to replace traditional drug therapy and generate significant revenue from the sales of personalized test devices. Moreover, various companies are investing in cost-effective biomarker-based tests to expand their market reach. Regulatory approvals for these tests, strategic partnerships among vendors, and an increase in product launches are also expected to fuel the growth of the global immunodiagnostics market during the forecast period.
Browse market data tables, figures, and in-depth TOC on “Immunodiagnostics Market” by Product (Reagents and consumables, Immunodiagnostic systems) Application (Oncology and endocrinology, Hepatitis and retrovirus, Infectious disease, GI stool, Other applications) Geography (North America, Europe, Asia, Rest of World (ROW)) Global Forecast to 2028. Download Free Sample
By Product, the Reagents and consumables segment is projected to dominate the market size in 2024
The escalating prevalence of chronic diseases such as cancer and diabetes necessitates the utilization of immunodiagnostic tests for early and accurate detection. In the realm of oncology, multiplex immunoassay tests, like VITROS Total PSA Assay II from Orthoclinical Diagnostics, are extensively employed for solid tumor analysis due to their ability to detect multiple markers simultaneously. These tests offer both low-range sensitivity and broad measuring ranges, enhancing patient monitoring and screening efficacy. In the context of diabetes, the rising number of diagnosed cases in the US and globally necessitates the development and implementation of advanced immunodiagnostic tools to ensure timely and accurate diagnosis and treatment.
By Application, Oncology and endocrinology segment is expected to hold the largest market size for the year 2024
The reagents and consumables segment is experiencing significant growth in the immunodiagnostics market, driven by the increasing demand for high-throughput screening using immunoassays. This trend has resulted in the production of innovative reagents for antigen detection, with advancements in fluorescence and chemiluminescence technology playing a pivotal role. The expanding range of immunodiagnostic tests necessitates companies to broaden their product portfolios, particularly in the reagent category. Notably, key players like Roche Diagnostics are capitalizing on this trend by manufacturing reagents for specific indications, such as oncology testing. Strategic partnerships are also common in the industry to enhance offerings and maintain a competitive edge in the immunodiagnostics market.
North America is forecasted to hold the largest market size by region in 2024
The Immunodiagnostics market represents a significant growth opportunity for businesses in the healthcare industry. This sector is driven by the increasing prevalence of chronic diseases, rising demand for personalized medicine, and advancements in diagnostic technologies. Immunodiagnostics offers accurate and early detection of diseases through the identification of specific antigens or antibodies, providing valuable insights for effective treatment plans and improved patient outcomes. Companies investing in this market can anticipate substantial returns as the global Immunodiagnostics market is projected to reach a value of USDXXX billion by XXYY, growing at a CAGR of XX%.
The Immunodiagnostics Market growth and forecasting report also includes detailed analyses of the competitive landscape of the market growth and forecasting and information about 20 market companies, including:
.
For insights on company offerings- Request a sample report!
Research Analysis Overview
Immunodiagnostics is an essential segment of the healthcare industry, particularly in the fields of oncology and endocrinology. The market for immunodiagnostics includes reagents and consumables used in the prevention from diseases through early diagnosis. In developed nations, the demand for immunodiagnostics is high due to increasing healthcare expenditures and an aging population with a higher prevalence of chronic diseases such as cancer, cardiovascular diseases, gastrointestinal diseases, hepatitis B, STI, autoimmunity diseases, and infectious diseases. Pathologists use various assays and diagnosis kits based on the antigen-antibody reaction to identify diseases. The supply chain network for immunodiagnostics is critical to ensure patient outcomes, and cost management is a significant challenge due to the high cost of analyzers and reagents. The lifestyle and demographics of the population also influence the demand for immunodiagnostics. The geriatric population, in particular, is at a higher risk for chronic diseases, making early diagnosis crucial. Overall, the immunodiagnostics market plays a vital role in improving patient outcomes while managing healthcare expenditures.
Market Research Overview
The Immunodiagnostics Market encompasses a broad range of diagnostic tests used for the detection and quantification of proteins, biomolecules, and antigens from various organisms, plant material, and natural processes. This market caters to various healthcare settings, including physician offices, clinics, hospitals, and diagnostic laboratories. The Oncology & Endocrinology segment holds a significant share due to the increasing prevalence of endocrine diseases, cancer, and autoimmune disorders. Key applications include the detection of cardiac markers, hepatitis & retrovirus, and respiratory infections. Reagents & consumables, diagnostic kits, and diagnostic platforms are the major product categories. New product approvals, pricing analysis, and pipeline analysis are crucial aspects of this market. Immunodiagnostics play a pivotal role in prevention from diseases through early diagnosis, especially in developed nations, where healthcare expenditures are high. Technological advancements, such as chemiluminescence immunoassay (CLIA), Radioimmunoassay (RIA), HPLC, and Flow cytometer, are driving market growth. The market is influenced by healthcare regulatory scenarios, false results, and technical limitations. Stringent regulatory requirements, biomarker discovery, and stringent quality control measures are key challenges. The market is served by various stakeholders, including Druggists, Pharmaceutical industries, Clinical laboratories, and Pathological labs. Immunodiagnostics have significant applications in various diseases, including autoimmune diseases, hepatitis, HIV, STI, Chikungunya, Dengue, and others. The aging population, chronic diseases, gastrointestinal diseases, and cardiovascular diseases are key disease areas. Lifestyle and demographics also influence market trends. Immunodiagnostics are used in various healthcare settings, including hospital wards, clinical biochemistry laboratories, hematology sections, histopathology, clinical microbiology departments, and serological labs. Assays, such as Rheumatoid factor tests and Immunoglobulin tests, are commonly used. In conclusion, the Immunodiagnostics Market is a dynamic and growing industry, driven by the need for early disease detection, technological advancements, and regulatory requirements. It plays a crucial role in improving patient outcomes and managing healthcare expenditures.
Contacts
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/
